AnBogen Reveals Dual Attack on Hard-to-Treat Cancers at AACR 2026

TAIPEI, Taiwan – April 13, 2026 – Clinical-stage biotech firm AnBogen Therapeutics is set to unveil promising new data on its lead compound, Imofinostat (ABT-301), positioning the drug as a potential two-pronged weapon against some of oncology's most stubborn targets: advanced colorectal and pancreatic cancers. The company announced that two pivotal research abstracts have been accepted for presentation at the prestigious 2026 American Association for Cancer Research (AACR) Annual Meeting in San Diego.

The findings highlight Imofinostat's ability to fundamentally alter the tumor battlefield, enhancing immunotherapy in colorectal cancer and dismantling chemotherapy resistance in pancreatic cancer. This dual breakthrough provides a powerful scientific rationale for the company's ongoing clinical trials and its broader strategy in the competitive precision oncology landscape.

Turning 'Cold' Tumors 'Hot' in Colorectal Cancer

One of the greatest challenges in modern oncology is the limited efficacy of immune checkpoint inhibitors (ICIs) in a large subset of cancers. In metastatic colorectal cancer (mCRC), this problem is particularly acute. Approximately 95% of patients have tumors classified as proficient mismatch repair (pMMR) or non-microsatellite instability-high (non-MSI-H). These are often dubbed immunologically "cold" tumors, characterized by a lack of immune cell infiltration, rendering them largely invisible and unresponsive to blockbuster immunotherapies.

AnBogen's preclinical data, to be presented at AACR, demonstrates that Imofinostat may hold the key to heating up these cold tumors. As a small-molecule Histone Deacetylase inhibitor (HDACi), Imofinostat works epigenetically to reactivate silenced tumor-suppressor genes. The research shows it effectively modulates the tumor microenvironment (TME), creating a more favorable setting for an anti-cancer immune response. By synergizing with ICIs and anti-angiogenic agents, it helps recruit the body's own immune cells into the tumor core, effectively transforming it from "cold" to "hot."

This mechanism is the cornerstone of AnBogen's triple combination strategy, which is currently being evaluated in a global Phase 1/2 clinical trial (NCT07244705). The study combines oral Imofinostat with Tislelizumab (an anti-PD-1 antibody) and Bevacizumab (an anti-angiogenic agent) for patients with advanced pMMR/non-MSI-H mCRC. The strategy is designed for maximum synergy: Imofinostat primes the tumor for attack, Tislelizumab releases the brakes on the immune system, and Bevacizumab normalizes tumor blood vessels to improve drug delivery and immune cell access. Notably, Imofinostat has shown a favorable safety profile in earlier monotherapy trials, lacking the cardiac toxicity or neutropenia common to other HDAC inhibitors, making it a more attractive partner for combination regimens.

Cracking the Code of Pancreatic Cancer Resistance

AnBogen's second AACR presentation tackles an even more formidable foe: KRAS-mutant pancreatic ductal adenocarcinoma (PDAC). With a five-year survival rate often languishing in the single digits, PDAC is notoriously aggressive and resistant to treatment. A key reason is the prevalence of KRAS mutations (found in over 90% of cases), which drive tumor growth and create powerful resistance to chemotherapy.

The new research reveals a novel mechanism by which Imofinostat can overcome this resistance. The study shows the drug precisely regulates the HDAC3-NRF2 signaling pathway, a critical network that cancer cells hijack to survive chemotherapy. By intervening in this pathway, Imofinostat was shown to significantly boost the tumor's sensitivity to standard chemotherapeutic agents.

This finding is particularly significant because the NRF2 pathway is a known double-edged sword. While it protects normal cells from stress, its over-activation in cancer promotes survival and resistance. Developing a therapy that can modulate this pathway to re-sensitize tumors to treatment, rather than inadvertently bolstering their defenses, represents a sophisticated and potentially transformative approach for patients with this devastating disease.

From Lab Bench to Market: A Well-Funded Strategy

The scientific validation from AACR arrives as AnBogen executes a well-defined corporate strategy backed by significant financial momentum. The company recently completed successful Series A and A+ funding rounds, securing nearly $20 million USD to advance its pipeline. It has also launched a Series B round and recently began trading on the Taipei Exchange's Emerging Stock Board (stock code: 7784), signaling its readiness for public market exposure and global expansion.

This financial foundation is critical for translating complex science into patient-ready therapies. The upcoming presentations bolster the company's value proposition as it seeks to accelerate its clinical programs.

"The two abstracts presented at AACR this year represent international academic recognition of ABT-301's innovative mechanism," said John Hsu, CEO of AnBogen Therapeutics, in a statement. "We are accelerating the translation of these findings into clinical results. Furthermore, our recent successful Series B funding and upcoming plans for an Emerging Stock Market listing will provide the resources needed to drive our trials forward and address significant unmet medical needs."

Beyond Imofinostat, AnBogen's pipeline includes a HER2-targeting inhibitor and a series of small molecules aimed at the historically "undruggable" pan-KRAS target, underscoring its deep commitment to precision oncology. This multi-pronged approach, targeting both the cancer cell's internal machinery and its surrounding microenvironment, places the company at the forefront of a major paradigm shift in cancer treatment. This synergistic strategy, which aims to dismantle a tumor's defenses from multiple angles simultaneously, represents a critical evolution in the ongoing battle against the world's most formidable malignancies.